ArticleFrontiers in immunology2025

A high content clonogenic survival drug screening identifies maytansine as a potent radiosensitizer for meningiomas.

Jinxiu Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.